TABLE 2

Characteristics of TST-Positive (≥10 mm) Schoolchildren and Their Child Associates Presenting at the TB Clinic

VariableSchoolchildren (n = 484)Associates (n = 131)a
Gender, n (%)
    Male257 (53.1)70 (53.4)
Age, y
    Mean12.411.6
    Range5.0–18.41.2–17.8
Region of origin, n (%)
    East/Southeast Asia121 (25.0)19 (14.6)
    Eastern Europe102 (21.1)24 (18.5)
    Central Asia67 (13.8)21 (16.2)
    South Asia67 (13.8)32 (24.6)
    South/Central America39 (8.1)11 (8.5)
    North Africa/Middle East28 (5.8)7 (5.3)
    Caribbean22 (4.5)8 (6.1)
    Sub-Saharan Africa20 (4.1)4 (3.0)
    North America/Western Europe18 (3.7)4 (3.0)
Years since immigration to Canada, n (%)
    <1156 (32.2)52 (39.7)
    1–2242 (50.0)63 (48.1)
    ≥286 (17.8)16 (12.2)
Vaccinated (BCG), n (%)b
    Yes407 (84.1)104 (79.4)
    No22 (4.5)4 (3.1)
    Unknown55 (11.4)23 (17.6)
Previous TST, n (%)b
    Yes127 (26.2)27 (20.6)
    No221 (45.6)59 (45.0)
    Unknown136 (28.1)45 (34.4)
Chest radiograph results, n (%)
    Normal413 (85.3)113 (86.3)
    Abnormal, not TB39 (8.1)5 (3.8)
    Abnormal, TB21 (4.3)0 (0.0)
    Missing11 (2.3)13 (9.9)
Started on drug treatment, n (%)
    Yes377 (77.9)108 (82.4)
    No66 (13.6)10 (7.7)
    Refused36 (7.4)12 (9.2)
    Unknown5 (1.0)1 (0.8)
Type of drug treatment given, n (%)c,d
    INH370 (98.1)106 (98.1)
    Rifampin2 (0.5)1 (0.9)
    Other0 (0)0 (0.0)
    Unknown5 (1.3)1 (0.9)
Duration of treatment, n (%)c,d
    ≤6 mo7 (1.9)3 (2.8)
    9 mo365 (96.8)103 (95.4)
    12 mo1 (0.3)0 (0)
    Unknown4 (1.1)2 (1.9)
Adherence to treatment, n (%)c,d
    Good316 (83.8)94 (87.0)
    Poor26 (6.9)5 (4.6)
    Unknown35 (9.3)9 (8.3)
Treatment adverse effects, n (%)c,d
    Yese22 (5.8)6 (5.6)
    No314 (83.3)81 (75.0)
    Unknown41 (10.9)21 (19.4)
Loss to follow-up, n (%)c,d
    None278 (73.7)91 (84.3)
    Moved23 (6.1)2 (1.9)
    Dropped out55 (14.6)7 (6.5)
    Unknown21 (5.6)8 (7.4)
Family members screened, n (%)
    0139 (28.7)NA
    1–3226 (46.7)NA
    ≥445 (9.3)NA
    Unknown74 (15.3)NA
  • NA indicates not applicable.

  • a Children aged <18 years.

  • b Self-reported.

  • c Among those who had been started on treatment(n = 377).

  • d For associates: only among children started on treatment at MCH (n = 108).

  • e The most common adverse effects for schoolchildren were abdominal pain (n = 9), weight loss (n = 3), and headache (n = 2).